Downstream Processing

Repligen talks product diversification through M&A and R&D

Exclusive interview from Biotech Week Boston

Balancing the up and downstream: Repligen CEO talks R&D and M&A

By Dan Stanton

Repligen’s customer GE Healthcare opted to make its latest Protein A ligand in-house, but CEO Tony Hunt remains confident in his firm’s long-term partnerships and diversified bioprocessing offering.

Follow us

Products

View more

Webinars